Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Janux Therapeutics (JANX) over the last 6 years, with Sep 2025 value amounting to $9.0 million.

  • Janux Therapeutics' Share-based Compensation fell 41.22% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 18.25%. This contributed to the annual value of $33.0 million for FY2024, which is 65.06% up from last year.
  • Latest data reveals that Janux Therapeutics reported Share-based Compensation of $9.0 million as of Q3 2025, which was down 17.48% from $11.0 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Share-based Compensation high stood at $15.4 million for Q3 2024, and its period low was $123,000 during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $5.8 million (2024), whereas its average is $7.6 million.
  • Per our database at Business Quant, Janux Therapeutics' Share-based Compensation spiked by 63,750.00% in 2021 and then crashed by 41.22% in 2025.
  • Janux Therapeutics' Share-based Compensation (Quarterly) stood at $2.9 million in 2021, then surged by 42.83% to $4.2 million in 2022, then rose by 6.61% to $4.5 million in 2023, then skyrocketed by 39.44% to $6.3 million in 2024, then plummeted by 41.22% to $9.0 million in 2025.
  • Its last three reported values are $9.0 million in Q3 2025, $11.0 million for Q2 2025, and $10.7 million during Q1 2025.